LISTEN: 2011 STOCKGURU INTERVIEW WITH STEPHEN ROSS OF REMEDENT
Remedent, Inc. (REMI), an international company specializing in research, development, and manufacturing of oral care and cosmetic dentistry products, reported results for the fourth quarter and for the year ended March 31, 2012 (in US Dollars).
Conference Call Information:
Remedent will host a conference call on Tuesday, July 17, 2012 at 12:00 p.m. Eastern Daylight Time (9:00 a.m. Pacific Daylight Time) to discuss these results and its strategic plans for the future. A question and answer session will follow management’s presentation.
To participate in this call, dial the appropriate number 5-10 minutes prior to the start time.
Date: Tuesday, July 17, 2012
Time: 12:00 p.m. Eastern Daylight Time. (9:00 a.m. Pacific Daylight Time)
Dial in Number: 1-888-329-8862
A telephone replay of the call will be available until July 31, 2012
Toll Free Replay Number: 888-203-1112
Replay Password: 5409163
About Remedent
Remedent, Inc. specializes in the research, development, manufacturing and marketing of oral care and cosmetic dentistry products. The company serves professional dental industry with breakthrough technology for dental veneers. These products are supported by a line of professional veneer whitening and teeth sensitivity solutions. Headquartered in Belgium, Remedent distributes its products to more than 28 countries worldwide. For more information, go to www.remedent.com.
Forward-Looking Statements
Statements in this press release that are “forward-looking statements” are based on current expectations and assumptions that are subject to risks and uncertainties. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Remedent’s actual operating results to be materially different from any historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements that explicitly describe these risks and uncertainties, readers are urged to consider statements that contain terms such as “believes,” “belief,” “expects,” “expect,” “intends,” “intend,” “anticipate,” “anticipates,” “plans,” “plan,” “projects,” “project,” to be uncertain and forward-looking. Actual results could differ materially because of factors such as Remedent’s ability to achieve the synergies and value creation contemplated by the proposed transaction. For further information regarding risks and uncertainties associated with Remedent’s business, please refer to the risk factors described in Remedent’s filings with the Securities and Exchange Commission, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. We undertake no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release.
REMI Disclosure: Pentony Enterprises LLC entered into an investor relations consulting and market awareness contract on December 21, 2010. REMI has agreed to compensate us five thousand dollars for coverage. We have taken no free trading shares. To avoid all potential conflicts of interest, we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. We hold only restricted shares and will not register or sell these shares at anytime during the promotional period. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
